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ABSTRACT
The United States Supreme Court decided six very important patent cases in the 2016-17 term,
Samsung Electronics Co., Ltd. v. Apple Inc., called the “design patent case of the century,” Life
Technologies Corp. v. Promega Corp., an international supply chain patent case, SCA Hygiene Products
v. First Quality Baby Products, LLC, where the doctrine of laches was not a defense in a patent
infringement case, TC Heartland LLC v. Kraft Foods Group Brands LLC, which dealt with patent
venue statute, Impression Products, Inc. v. Lexmark International, Inc., which held that the authorized
first sale of a patented item exhausts the patent holder’s rights, and Sandoz Inc. v. Amgen Inc., which
interpreted the Biologics Price Competition and Innovations Act. In each case, the Court of Appeals
for the Federal Circuit was reversed, vacated, or both. Four of the cases were unanimous, and two
had only one dissenter each, Justice Breyer and Justice Ginsburg, which sends a strong message from
the Court in the area of patent law, as well as a strong message to the Court of Appeals for the Federal
Circuit. This article reviews the six Supreme Court patent decisions and concludes with implications
of this series of important cases.
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I. INTRODUCTION
Congress has the power “[t]o promote the progress of science and useful arts,
by securing for limited times to authors and inventors the exclusive right to
their respective writings and discoveries.”1
The United States Supreme Court decided six very important patent cases in the
2016-17 term, Samsung Electronics Co., Ltd. v. Apple Inc.,2 Life Technologies Corp. v.
Promega Corp.,3 SCA Hygiene Products v. First Quality Baby Products, LLC,4 TC
Heartland LLC v. Kraft Foods Group Brands LLC,5 Impression Products, Inc. v.
Lexmark International, Inc.,6 and Sandoz Inc. v. Amgen Inc.7 In each case, the Court
of Appeals for the Federal Circuit became reversed, vacated, or both. Four of the cases
were unanimous, and two had only one dissenter each, Justice Breyer and Justice
Ginsburg, which sends a strong message from the Court in the area of patent law, as
well as a strong message to the Court of Appeals for the Federal Circuit.
In Samsung v. Apple, on December 6, 2016, the Supreme Court held unanimously
that the “article of manufacture” for design patent infringement damages cases could
be a component of a product, and not just the entire end product.8 In this case, the
entire profits from Samsung’s smartphones found infringing upon Apple’s design
patents were initially awarded, but the Supreme Court reversed the decision of the

* © Sue Ann Ganske 2017. Clinical Professor of Business Law, School of Accounting, College of
Business, Florida International University; J.D., University of Toledo College of Law, Order of the
Coif, Business Editor, Law Review; M.A. and B.A., Bowling Green State University.
1 U.S. CONST., art. I, § 8, cl. 8.
2 Samsung Elecs. Co. v. Apple Inc., 137 S. Ct. 429, 196 L. Ed. 2d 363 (2016).) See infra notes
29-75 and accompanying text.
3 Life Techs. Corp. v. Promega Corp., 137 S. Ct. 734, 197 L. Ed. 2d 33 (2017). See infra notes
76-120 and accompanying text.
4 SCA Hygiene Prod. Aktiebolag v. First Quality Baby Prod., LLC, 137 S. Ct. 954, 197 L. Ed. 2d
292 (2017). See infra notes 121-155 and accompanying text.
5 TC Heartland LLC v. Kraft Foods Grp. Brands LLC, 137 S. Ct. 1514, 197 L. Ed. 2d 816 (2017).
See infra notes 156-190 and accompanying text.
6 Impression Prod., Inc. v. Lexmark Int’l, Inc., 137 S. Ct. 1523, 198 L. Ed. 2d 1 (2017). See infra
notes 191-250 and accompanying text.
7 Sandoz Inc. v. Amgen Inc., 137 S. Ct. 1664, 198 L. Ed. 2d 114 (2017). See infra notes 251-309
and accompanying text.
8 Samsung Elecs. Co., 137 S. Ct. at 434.
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Court of Appeals for the Federal Circuit, and remanded,9 leaving the test to be used
on remand for a later day, since it wasn’t before the Court because the parties hadn’t
briefed the issue.10 This very important case has been called the “design patent case
of the century,”11 and is also the first design patent damages case in over a century.12
In Life Technologies v. Promega, the Supreme Court on February 22, 2017 held
seven to zero with a concurrence in part, that in the international supply chain,
supplying a “substantial portion” of a patented invention from the United States,
which could give rise to infringement under the Patent Act,13 is a quantitative
assessment, and requires more than one component supplied from the U.S.,14 reversing
the decision of the Federal Circuit and remanding.15
In SCA Hygiene Products v. First Quality Baby Products, LLC,16 the Supreme
Court on March 21, 2017 held seven to one that the doctrine of laches had no
availability as a defense to a patent infringement case during the six-year patent
statute of limitations, vacating the en banc decision of the Court of Appeals for the
Federal Circuit and remanding the case. Justice Breyer dissented.17
In TC Heartland v. Kraft Foods Brand Group,18 the Supreme Court on May 22,
2017 held eight to zero that a corporation resides only in its state of incorporation for
purposes of the specific patent venue statute,19 reversing and remanding the Court of
Appeals for the Federal Circuit. This case restricts the jurisdiction in which patent
infringement cases may be filed, and although this case did not involve a patent nonpracticing entity or patent troll, nor did it even mention the term, curtailed the forums
in which patent trolls or any patent infringement plaintiff may bring suit, thus is a
very important decision during this term.
In Impression Products, Inc. v. Lexmark Int’l., Inc., another very important patent
case, the Supreme Court held eight to zero that an authorized first sale of a patented
product in the United States exhausts the patent holder’s right in that product, and
seven to one with Justice Ginsburg dissenting that patent exhaustion applies to the
first sale of a patented product outside the United States.20 Again, the Court of
Appeals for the Federal Circuit became reversed and remanded.21 The patent holder
may use contract restrictions with the purchaser, but may not use a patent
Id. at 436.
Id.
11 Apple v. Samsung: Design Patent Case of the Century, NATIONAL LAW REVIEW (Aug. 1, 2016),
available at http://www.natlawreview.com/article/apple-v-samsung-design-patent-case-century.
12 In 1886, the Supreme court decided Dobson v. Dornan on U.S. design patents D10,778, D10,870,
and D11,034 on carpet designs. 118 U.S. 10 (1886). The prior year, the Court decided Dobson v.
Hartford Carpet Co., which awarded six cents in damages on U.S. Pat. D6,832, also on carpets. 114
U.S. 439 (1885). The Patent Act was changed subsequent to these cases.
13 35 U.S.C. § 271(f)(1).
14 Life Techs. Corp., 137 S. Ct. at 743.
15 Halo Elecs., Inc. v. Pulse Elecs., Inc., 831 F.3d 1369, 1380 (Fed. Cir. 2016).
16 SCA Hygiene Prod. Aktiebolag, 137 S. Ct. at 966.
17 Id. at 967.
18 TC Heartland LLC v. Kraft Foods Grp. Brands LLC, 137 S. Ct. 1514, 197 L. Ed. 2d 816 (2017).
19 28 U.S.C. § 1400(b).
20 See generally Impression Prod., Inc. v. Lexmark Int’l, Inc., 137 S. Ct. 1523, 198 L. Ed. 2d 1
(2017).
21 Id.
9

10
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infringement case against a company such as Impression Products who refurbished
and resold Lexmark toner cartridges.22
In Sandoz Inc. v. Amgen Inc.,23 the full Court unanimously, with one concurrence,
interpreted the Biologics Price Competition and Innovation Act, holding that a
biological biosimilar applicant not participating in the first step of the Act does not
subject the applicant to an injunction, and the applicant may give the reference product
manufacturer the required 180-day notice of commercial marketing under the Act
before the FDA licensure of the biosimilar product. The Court both vacated and
reversed the Court of Appeals for the Federal Circuit, and remanded.24
The six patent decisions of 2016-17 tied the record-setting six patent decisions by
the Court in 2014,25 but in the recent term, the Court of Appeals became reversed,
vacated, or both every time.26 The theme of the Supreme Court in the six patent
decisions in 2016-17, if there is a theme, is that the Court of Appeals for the Federal

22 Id. Impression Products did not have the contract with Lexmark, the purchaser did, which
makes the contract solution more difficult.
23 Sandoz Inc. v. Amgen Inc., 137 S. Ct. 1664, 198 L. Ed. 2d 114 (2017).
24 Id.
25 See generally Sue Ann Ganske, Cuozzo Speed Technologies, LLC, and Halo Electronics, Inc.:
The U.S. Supreme Court Issues Two Patent Decisions in 2016, Upholding a Section of the America
Invents Act and Respecting Established Patent Principles, accepted for Publication in the Texas
Intellectual Property Law Journal, forthcoming 2017, 25 TEXAS I. P. L. J. _ (2017); Sue Ann Ganske,
Marvel, Cisco, and Teva: The Supreme Court Decides Three Patent Cases in 2015, Respecting Stare
Decisis, 24 TEXAS I.P. L. J. 1 (2016); Sue Ann Ganske, The U.S. Supreme Court Decides Six Patent
Cases in 2014, Culminating in Alice Corp. v. CLS Bank International, 23 TEXAS I.P. L. J. 183 (2015).
The other term with six patent cases, 2014, had all six decided unanimously by the Court.
26 In 2016, Judge Dyk of the Court of Appeals for the Federal Circuit wrote that in the prior
decade, the Supreme Court took on average four cases from the Federal Circuit per year, with an
average reversal rate of 70% over the past decade, which is just slightly above the circuit median
average of 66.7%. The 5th, 11th, 8th, 9th, and 6th circuits have higher reversal rates, in increasing order.
The Honorable Timothy B. Dyk, Thoughts on the Relationship between the Supreme Court and the
Federal Circuit, 16 CHI. KENT J. INTELL. PROP. 67 (2016). Nonetheless, the data from the 201617 term will raise this reversal rate, and possibly the ranking of the Federal Circuit in terms of
reversals by the Supreme Court. In 2016-17, the Supreme Court 6-2 affirmed the Federal Circuit in
Cuozzo, supra note 2. In 2016, the Court unanimously reversed the Federal Circuit in Halo, supra
note 3. In 2015, in Teva Pharmaceuticals USA v. Sandoz, 135 S. Ct. 831 (2015), the Court vacated
the Court of Appeals of the Federal Circuit and remanded, seven to two. In Commil USA, LLC v.
Cisco Systems, Inc., 135 S. Ct. 1920 (2015), the Court again vacated the Court of Appeals for the
Federal Circuit and remanded. In Kimble v. Marvel Entm’tEntm’t, LLC, 135 S. Ct. 2401, 192 L. Ed.
2d 463 (2015), the Court of Appeals for the Ninth Circuit was affirmed. In 2014, in Medtronic, Inc. v.
Mirowski Family Ventures, LLC, 134 S. Ct. 843 (2014), the Supreme Court unanimously reversed the
Court of Appeals for the Federal Circuit, and remanded. In Octane Fitness, LLC. V. Icon Health &
Fitness, Inc., 134 S. Ct. 1749 (2014), the Court unanimously reversed the Federal Circuit and
remanded. In Highmark Inc. v. Allcare health Management System, Inc., 134 S. Ct. 1744 (2014), the
Court unanimously vacated the Federal Circuit’s decision and remanded. In Limelight Networks, Inc.
v. Akamai Technologies, Inc., 134 S. Ct. 2111 (2014), the Supreme Court unanimously reversed the
Federal Circuit and remanded the case. In Nautilus, Inc. v. Biosig Instruments, Inc., 134 S. Ct. 2120
(2014), the Supreme Court unanimously vacated the decision from the Court of Appeals for the
Federal Circuit and remanded. In Alice Corp. v. CLS Bank Int’lInt’l, 134 S. Ct. 2349 (2014), affirmed
the Court of Appeals for the Federal Circuit unanimously.
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Circuit should be attentive to Supreme Court precedence27 and statutory language.28
Each case is essential to intellectual property law and practice, and this article reviews
and analyzes the six Supreme Court patent decisions of 2016-17. This article concludes
with implications from this term of patent cases.
II. SAMSUNG ELECTRONICS CO., LTD. V. APPLE INC.
Whoever during the term of a patent for a design, without license of the
owner, (1) applies the patented design, or any colorable imitation thereof, to
any article of manufacture for the purpose of sale, or (2) sells or exposes for
sale any article of manufacture to which such design or colorable imitation
has been applied, shall be liable to the owner to the extent of his total profit.29
But, what is that “article of manufacture” from this section of the Patent Act for
computing design patent infringement damages? Is it the entire end product, as the
Court of Appeals for the Federal Circuit held,30 or may it be a component of the end
product? The Supreme Court on December 6, 2016 in Samsung v. Apple held that the
“article of manufacture” of the Patent Act,31 above, not necessarily constituted the end
product, a smartphone, but could be a component of the end product.32 The Court of
Appeals for the Federal Circuit ruled to the contrary. The Supreme Court thus
unanimously reversed the Court of Appeals for the Federal Circuit and remanded.33
Apple Inc. became incorporated in 1977 in California,34 and “designs,
manufactures, and markets mobile communication and media devices and personal
computers,” and sells software and sells these and other products and services.35
Samsung Electronics Co., Ltd. became incorporated in South Korea in 1969, and has
three business divisions: consumer electronics, information technology and mobile
devices, and device solutions.36 In the first quarter of 2017, Samsung stood as the
world’s top smartphone manufacturer, with a 20.7% market share, and Apple followed
with a 13.7% market share, both down from the first quarter of 2016.37
27 See SCA Hygiene, infra notes 121-155, TC Heartland, infra notes 156-190 and accompanying
text, and Impression Products, infra notes 191-250 and accompanying text.
28 See Sandoz, infra notes 251-309 and accompanying text.
29 35 U.S.C. § 289. “Section 289 of the Patent Act provides a damages remedy specific to design
patent infringement.” Samsung Elecs. Co., 137 S. Ct. at 431.
30 Apple Inc. v. Samsung Elecs. Co., Ltd., 786 F.3d 983, 1005 (Fed. Cir. 2015).
31 35 U.S.C. § 289.
32 Samsung Elecs. Co v. Apple Inc., 137 S. Ct. 429, 196 L. Ed. 2d 363 (2016).
33 Id. at 436.
34 Frequently Asked Questions, INVESTOR RELATIONS (last visited June 6, 2017), available at
http://investor.apple.com/faq.cfm.
35 Apple, Inc. SEC Form 10-Q for Quarter ended April 30, 2017, APPLE INC. (last visited June 6,
2017), available at http://files.shareholder.com/downloads/AAPL/4370400879x0x940908/7A9E0B417A91-4A6D-95A4-636BA686B219/10-Q_Q2_2017_As-Filed_.pdf.
36 Independent Auditor’s Review Report, SAMSUNG ELECTRONICS, CO., LTD., first quarter 2017
(last
visited
June
6,
2017)
http://images.samsung.com/is/content/samsung/p5/sg/ir/docs/2017_con_quarter01_all.pdf.
37 Don Reisenger, Apple and Samsung Stumble as Smartphone Market Soars, FORTUNE (May 23,
2017), http://fortune.com/2017/05/23/apple-iphone-gartner-market-share/.
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In 2007, Apple released its iPhone smartphone, which had numerous design and
utility patents.38 Samsung released smartphones which resembled Apple’s iPhone.39
On April 15, 2011, Apple filed a patent infringement lawsuit alleging that Samsung
smartphones including the Galaxy S 4G infringed some of Apple’s design and utility
patents.40 Specifically, Apple’s complaint and amended complaint alleged that design
patents41 including U.S. Patent Number D593,087 (the ’087 patent)42 for “a rectangular
front face with rounded corners and a raised rim,”43 and U.S. Patent Number D618,677
(the ’677 patent)44 for “a black rectangular front face with rounded corners,”45 both at
issue in the appeal which reached the U.S. Supreme Court, for the ornamental design
of an electronic device, were infringed, among others.46 Apple requested a preliminary
injunction against Samsung’s devices which allegedly infringed, but the district court
denied the motion for the preliminary injunction.47 The Court of Appeals for the
Federal Circuit in 2012 affirmed the denial of the requested preliminary injunction for
products embodying the two design patents at issue in the Supreme Court case.48
After trial on August 24, 2012, the jury returned a verdict largely in Apple’s favor
on infringement of design and utility patents as well as trade dress dilution, and

Samsung Elecs. Co. v. Apple Inc., 137 S. Ct. at 433.
Id.
40 Apple, Inc. v. Samsung Electronics Co., Ltd., 678 F.3d 1314, 1319 (Fed. Cir. 2012). The lawsuits
between these companies extended globally as well. See generally, Jaemin Lee, A Clash Between IT
Giants and the Changing Face of International Law, 5 JEAIL 17 (2012). ITC Section 337 actions
were also involved. See Mark Kochuk, Note & Comment, In the Matter of Certain Electronic Devices:
Apple, Samsung, Patent Holdup, and Public Interest, 40 N. C. J. INT’L. L & COM. REG. 849 (2015).
41 “Whoever invents a new, original and ornamental design for an article of manufacture may
obtain a patent thereof . . . .”. 35 U.S.C. § 171(a).
42
U.S.
Patent
No.
D593,087
(May
26,
2009),
available
at
https://www.google.com/patents/USD593087.
43 Samsung Elecs. Co. v. Apple Inc., 137 S. Ct. at 433.
44
U.S.
Patent
No.
D618,677
(June
29,
2010)
available
at
https://www.google.com/patents/USD618677?dq=us+d618,677&hl=en&sa=X&ved=0ahUKEwii0eKO
g6rUAhUNySYKHf5dBSgQ6AEIKDAA.
45 Samsung Elecs. Co. v. Apple Inc., 137 S. Ct. at 433.
46 Apple also alleged that claims of U.S. Patent No. D504,889, and U.S. Patent No. 7,469,381, a
utility patent on the bounce-back feature on Apple’s iPhone and iPad were also infringed. Apple, Inc.,
678 F.3d at 1318. Samsung counterclaimed that Apple products infringed on claims of twelve
Samsung patents. Apple’s answer and counterclaims alleged that Samsung violated state and federal
antitrust law and California Unfair Competition Law, and Samsung’s motions to dismiss and strike
Apple’s counterclaims were granted in part. Apple, Inc. v. Samsung Electronics Co., Ltd., No. 11-CV10846-LHK, 2011 U.S. Dist. LEXIS 120416 at *1127-28, 1135 (N.D. Cal. Oct. 18, 2011).
47 Apple Inc. v. Samsung Electronics Co., Ltd., No. 11-cv-1846, 2011 U.S. Dist. LEXIS 139049
(N.D. Cal. Dec. 2, 2011).
48 Apple Inc. v. Samsung Electronics Co., Ltd., 678 F.3d 1314, 1333 (Fed. Cir. 2012). The denial
of the preliminary injunction on the ‘381 utility patent was also affirmed on May 14, 2012, but the
denial of the preliminary injunction on the ‘889 patent was vacated and remanded. Id. On June 26,
2012, the district court preliminarily enjoined Samsung from making, using, offering to sell, or selling
in the U.S. Samsung’s Galaxy Tab 10.1 tablet computer or any other product which embodied any
design contained in the ’889 patent. Apple, Inc. v. Samsung Electronics Co., Ltd., No. 11-CV-01846LHK, 2012 U.S. Dist. LEXIS 88436 at *24 (N.D. Cal. June 26, 2012). When the jury determined that
the ’889 design patent was not infringed, the district court lifted this preliminary injunction. Id. at
*51.
38
39
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awarded over $1 billion in damages.49 At issue in the Supreme Court opinion,
specifically, found infringement of the ’677 patent, the ’087 patent, and U.S patent no.
D604,305 (the ’305 patent)50 on a “grid of 16 colorful icons on a black screen.”51
Samsung, however, received a judgment as a matter of law because Apple’s damages
numbers relied on improper notice dates.52 The district court struck approximately
$410 million of the damages,53 and set a limited retrial on damages.54 On November
21, 2013, a jury after a six day trial awarded Apple approximately $290 million for the
struck damages for patent infringement,55 which, when added to the non-struck
damages, left damages of about $930 million,56 and $399 million by the time the case
reached the Supreme Court.57
After the initial trial, Apple requested a permanent injunction.58 Applying the
four-factor test set by the Supreme Court in eBay,59 the district court denied the
permanent injunction.60 The Court of Appeals for the Federal Circuit affirmed for the
design patents and trade dress in question, but vacated and remanded on the utility
patents at issue.61 On remand, the permanent injunction received, again, denial.62
49 Apple Inc. v. Samsung Electronics Co., Ltd., 727 F.3d 1214, 1217 (Fed. Cir. 2013). Specifically,
the jury found that 26 Samsung products infringed claims of Apple’s patents, or diluted trade dress.
Apple, Inc. v. Samsung Electronics Co., Ltd., No. 11-CV-01846-LHK, 2014 U.S. Dist. LEXIS 29721 at
*55 (N.D. Cal. March 6, 2014). See generally, Matthew Lammertse, Note, Apple v. Andoid: Global
Software Patentability and the Mobile OS Wars, 39 BROOKLYN J. INT’L. L. 793 (2014).
50
U.S.
Patent
No.
D604,305
(Nov.
17,
2009)
available
at
https://www.google.com/patents/USD604305?dq=D604,305&hl=en&sa=X&ved=0ahUKEwjW2u6oj6r
UAhWIwiYKHVwhALMQ6AEIKDAA, on a graphical user interface for a display screen or portion
thereof.
51 Samsung Elecs. Co. v. Apple Inc., 137 S. Ct. at 433.
52 Apple, Inc. v. Samsung Electronics Co., Ltd., No. 11-CV-01846-LHK, 2014 U.S. Dist. LEXIS
17204 at *42 (N.D. Cal. Feb. 7, 2014). Since Apple did not provide sufficient evidence to recalculate
damages due to proper notice dates, $410 million was knocked off the first award. Id. at *42-43.
53 Id. at *55.
54 Id. at *36; “A jury may not award lost profits in a patent case in the absence of ‘sound economic
proof.’” Id. at *25. Thus, the district court granted Samsung’s Emergency Motion to Enforce the Nov.
7, 2013 order, as well as the April 29, 2013 order. Id. at * 28.
55 Id. at *42. Nearly $114 of this became lost profits due to patent infringement of one of Apple’s
patents. Id. at *48. Over $34 million was for reasonable royalties. Id. at *55. Just over $142 million
was for infringement of the ’305 and ’677 patents. Id. at *63-64.
56 Id. at *56.
57 Samsung Elecs. Co. v. Apple Inc., 137 S. Ct. at 433.
58 Apple Inc. v. Samsung Electronics Co., Ltd., 909 F. Supp. 2d 1147 (N.D. Cal. 2012).
59 eBay v. MercExchange, LLC, 547 U.S. 388 (2006). See generally, Sue Ann Mota, eBay v.
MercExchange: Traditional Four Factor Test for Injunctive Relief Applies to Patent Cases, According
to the Supreme Court, 40 AKRON L. REV. 529 (2007).
60 Apple Inc. v. Samsung Electronics Co., Ltd., 909 F. Supp. 2d 1147, 1156-57 (N.D. Cal. 2012).
61 Apple Inc. v. Samsung Electronics Co., Ltd., 735 F.3d 1352 (Fed. Cir. 2013).
See generally,
Steven M. Amundson, Federal Circuit Decisions Concerning Smartphones Have Created Uncertainty
Regarding the Evidence Needed to Prove Irreparable Harm and Establish Entitlement to Injunctive
Relief, 42 RUTGERS COMP. & TECH. L. J. 231 (2016); Daniel Harris Brean, Will the “Nexus”
Requirement of Apple v. Samsung Preclude Injunctive Relief in the Majority of Patent Cases?: Echoes
of the Entire Market Value Rule, 51 SAN DIEGO L. REV. 153 (2014).
62 Apple Inc. v. Samsung Electronics Co., Ltd., No. 11-CV-01846-LHK, 2014 U.S. Dist. LEXIS
29721 at *123 (N.D. Cal. March 6, 2014). The district court concluded that “it would be inequitable
to enjoin Samsung’s products from U.S. markets. Id. at *122.
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On Samsung’s appeal of the validity of the utility patents, the design patent
infringements, the damages, and whether the trade dress is protectable, the Court of
Appeals ruled in favor of Apple on the first three, but agreed with Samsung on the
trade dress issue.63 Specifically, Samsung argued that the district court erred in
allowing the entire profits on allegedly infringing Samsung smartphones as damages;
Samsung argued that damages should be apportioned, and the profits awarded should
relate only to the infringing “article of manufacture,” and not the entire smartphone.64
The Court of Appeals for the Federal Circuit, however, did not agree with Samsung;65
the entire smartphone is the “article of manufacture,” since “consumers could not
separately purchase components of the smartphone,”66 and thus Samsung’s entire
profits related to infringing smartphone sales should go to Apple.67 Samsung received
grant for a writ of certiorari at the U.S. Supreme Court on the issue of when a design
patent is applied to a component of a product, should profits be limited only to the
component?68
The U.S. Supreme Court on December 6, 2016 unanimously held that the “article
of manufacture” for computing design patent infringement damages, could be a
component of a product and isn’t necessarily always the entire end product, reversing
the Court of Appeals for the Federal Circuit.69 Writing for the entire Court, Justice
Sotomayor stated that ascertaining design patent infringement damages under the
Patent Act70 is a two-step process. First, the court must determine what constitutes
the article of manufacture which infringes on the design patent. Second, the court
must determine the total profit attributable to that article of manufacture.71 The only
question resolved by the Court revolved around whether, in a multicomponent product,
the “article of manufacture” is always the end product, or whether it may be a
component of the product.72 According to the Court, an “article of manufacture” could
be the final product or a component thereof, “whether sold separately or not.”73 Thus,
the court of appeals erred by narrowly interpreting “article of manufacture” design
patent infringement damages to cover only damages on the end product, and not
damages on a component.74
The Supreme Court declined to develop a test to determine the relevant “article
of manufacture” for the first step of the two-step process to determine design patent
infringement damages as the issue had no briefing, leaving this for the Court of
Apple Inc., 786 F.3d at 1005.
Id. at 1001-02.
65 Id. at 1005.
66 Samsung Elecs. Co., 137 S. Ct. at 432
67 Apple Inc., 786 F.3d at 1002.
68 Samsung Elecs. Co v. Apple Inc., 136 S. Ct. 1453 (2016).
69 Samsung Elecs. Co. v. Apple Inc., 196 L. Ed. 2d 363 (2016).
70 35 U.S.C. § 289 (2017).
71 Samsung Elecs. Co., 137 S. Ct. at 434.
72 Id. In a single component product, the article of manufacture is always the end product.
73 Id. at 436. “The Patent Office and the courts have understood § 171 to permit a design patent
for a design extending to only a component of a multicomponent product.” Id. at 435. Further, the
Supreme Court has used the term “manufacture” to include the production of articles from raw
materials by giving them new forms or properties. Id., citing Diamond v. Chakrabarty, 447 U.S. 303,
308 (1980).
74 Samsung Elecs. Co., 137 S. Ct. at 436.
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Appeals for the Federal Circuit on remand.75 This may set the stage for this case to
return to the Supreme Court on the issue of the appropriate test to determine this key
issue.
III. LIFE TECHNOLOGIES CORP. V. PROMEGA CORP.
Whoever without authority supplies or causes to be supplied in or from the
United States all or a substantial portion of the components of a patented
invention, where such components are uncombined in whole or in part, in
such a manner as to actively induce the combination of such components
outside of the United States in a manner that would infringe the patent if
such combination occurred within the United States, shall be liable as an
infringer.76
Does the “substantial portion” of this subsection of the Patent Act have a
quantitative or a qualitative meaning? The Court of Appeals for the Federal Circuit
in Promega Corp. v. Life Technologies Corp.77 gave the phrase a qualitative meaning,
holding that one component could qualify for infringement. The decision of the Court
of Appeals for the Federal Circuit became, again, unanimously reversed and remanded
seven to zero78 by the Supreme Court in Life Technologies Corporation v. Promega
Corporation,79 wherein the Court gave the phrase a quantitative meaning, so that
supplying a single component from the United States does not confer infringement
under this subsection. Justice Sotomayor, again writing for the Court, stated that the
term “substantial portion” has a quantitative and not qualitative meaning, and “does
not cover the supply of a single component of a multicomponent invention.”80
Promega Corporation originated in 1978 in Madison Wisconsin and holds
“intellectual property rights and licenses in several key areas” including short tandem
repeat (STR) for human identification.81 Life Technology Corporation82 manufactured
genetic testing kits which contain components “for carrying out a multiplex
amplification of STR loci from DNA samples”83 for law enforcement for identification,
Id.
35 U.S.C. § 271(f)(1).
77 773 F.3d 1338 (Fed. Cir. 2014).
78 Justice Scalia passed on February 13, 2016. Biography of former Associate Justice Antonin
Scalia, available at https://www.supremecourt.gov/about/biographyScalia.aspx (last visited June 11,
2017). Chief Justice Roberts took no part in the decision. Life Techs. Corp. v. Promega Corp., 137 S.
Ct. 734, 197 L. Ed. 2d 33 (2017).) The Chief Justice owned 1,212 shares in Thermo Fisher Scientific,
which acquired Life Technologies. Letter from the Clerk of Court, SCOTUSBLOG (Jan. 4, 2017),
http://www.scotusblog.com/wp-content/uploads/2017/01/1-4-17-Letter-from-Clerk-in-No.-14-1538.pdf.
79 137 S. Ct. 734, 197 L. Ed. 2d 33 (2017).
80 Id. at 743.
81
Company
Information,
PROMEGA
(June
10,
2017))
available
at
https://www.promega.com/aboutus/company-information/#tab-1.
82 Life Technologies Corp. was acquired by Thermo Fisher Scientific in 2014. Life Technologies,
THERMO FISHER (June 10, 2017) available at https://www.thermofisher.com/us/en/home/brands/lifetechnologies.html.
83 Promega Corp. v. Life Technologies Corp., 773 F.3d 1338, 1344 (Fed. Cir. 2014).
75
76
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“and by clinical and research institutions for purposes such as analyzing cancer
cells.”84
These kits contain five components, one of which Life Technology
manufactured in the U.S. and then shipped to the United Kingdom, where the kits
were assembled and sold worldwide.85
Promega owned four patents and held the exclusive licensee of a fifth, the “Tautz”
patent,86 which became cross-licensed in 2006 for “Forensics and Human Identity
Applications”87 to a company later acquired by Life Technologies. In 2010, Promega
sued Life Technologies for infringement of claims of all five patents, alleging that Life
Technologies sold testing kits incorporating the technologies, beyond the scope of the
2006 cross license. Life Technologies answered that it the license covered all
applications, plus counterclaimed that claims of Promega’s patents were invalid. The
district court orally ruled that the cross-license was for live forensic law enforcement
purposes only, and all other sales were infringing.88 At trial, a jury found in Promega’s
favor and awarded $52 million in damages.89 The district court judge, however,
granted Life Technologies’ judgment as a matter of law, because Promega failed to
prove infringement.90 Under the Patent Act,91 infringement may be found if one
supplies from the United States “all or a substantial portion of the components of a
patented invention,” which are uncombined in whole or part, to actively induce the
combination of these components outside the United States in a way which would
infringe, had this occurred in the United States. The issue grappled with by the
district court, which became ruled the same way by the Supreme Court,92 is whether a
single component shipped out of the United States suffices.93 The district court94
looked to the next subsection of the Patent Act,95 which also includes similar wording,
“where such component is uncombined in whole or in part,” and the district court
concluded that Promega did not prove that Life Technologies’ accused products
contained a “substantial portion” of components from the United States, when only one
component came from the United States.96
Id.
Id.
86 U.S. Pat. RE37984, on a Process for analyzing length polymorphisms in DNA regions, called
the Tautz patent after one of the inventors, Diethard
Tautz, available at
http://www.google.com/patents/USRE37984. This patent expired in 2015, and all subsequent appeals
involved only prior infringement.
87 Promega, 773 F.3d at 1344.
88 Id.
89 Promega Corp. v. Life Technologies Corp., No. 10-cv-281-bbc, 2012 U.S. Dist. LEXIS 190681
(W.D. Wis. Sept. 13, 2012).
90 Id. at *6.
91 35 U.S.C. § 271(f)(1).
92 Life Techs. Corp., 137 S. Ct. at 739.
93 Promega Corp. v. Life Technologies Corp., No. 10-cv-281-bbc, 2012 U.S. Dist. LEXIS 190681 at
*16 (W.D. Wis. Sept. 13, 2012).
94 Id. at *18.
95 35 U.S.C. § 271(f)(2) (2017).
96 Promega Corp. v. Life Technologies Corp., No. 10-cv-281-bbc, 2012 U.S. Dist. LEXIS 190681 at
*23 (W.D. Wis. Sept. 13, 2012). Promega also failed on its infringement claim under 35 U.S.C. § 271(a),
the whoever makes, uses, offers to sell, or sells any patented invention within the United States or
imports into the United States any patented invention is an infringer section, because Promega did
not provide evidence on this point. Id. at *30-31.
84
85
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Promega appealed the judgment as a matter of law, and Life Technologies
appealed the oral ruling that the cross-license didn’t cover all its products, plus that
asserted claims of Promega’s four patents were found not invalid.97 On appeal, the
Court of Appeals for the Federal Circuit found the patent claims in question invalid,
but also reversed Life Technologies’ judgment as a matter of law on the infringement
issue and remanded; the oral ruling upheld the cross license, however.98 Addressing
the issue before the Supreme Court concerning infringement by supplying from the
United States a substantial portion of the components, the appeals court disagreed
with the district court that a single component can never constitute a substantial
portion of the components of the patented invention.99
Judge Prost dissented in part, and agreed with the district court the Life
Technologies should not be liable for infringing by supplying the one component of the
kit from the United States,100 but not for the reason of the district court,101 and later
the Supreme Court.102 Judge Prost didn’t reach the single component infringement
issue, but rather that the Patent Act subsection103 requires inducement of another to
infringe, and Life Technologies could not be liable for that, since it only induced its
own subsidiary, and not another. Judge Prost, thus, would have held that no
infringement liability occurred from Life Technologies supplying from the United
States because one cannot induce oneself to infringe.104
The U.S. Supreme Court granted the writ of certiorari105 on the sole issue of
“whether the Federal Circuit erred in holding that supplying a single, commodity
component of a multi-component invention from the United States is an infringing act
under 35 U.S.C. § 271(f)(1), exposing the manufacturer to liability for all worldwide
sales.”106 On February 22, 2017, the Supreme Court unanimously held that the
Federal Circuit did err, because a single supplied component is not a substantial
portion of the components, reversing and remanding.107
Justice Sotomayor, again writing for the Court, stated her opinion, “this case
concerns the intersection of international supply chains and federal patent law.”108
The Court had to determine whether “substantial portion” constituted qualitative as
the Federal Circuit and Promega believed, or quantitative, as Life Technologies

Promega Corp. v. Life Technologies Corp., 773 F.3d 1338, 1341 (Fed. Cir. 2014).
Id.
99 Id. at 1356. See generally, Michael Sanzo, Exporting Components of Patented Products: A
Unique Way to Infringe, 18 N.C. J. L. & TECH. ON. 322 (2017).
100 Promega, 773 F.3d at 1358.
101 Promega Corp. v. Life Technologies Corp., No. 10-cv-281-bbc, 2012 U.S. Dist. LEXIS 190681
at *23 (W.D. Wis. Sept. 13, 2012).
102 Life Techs. Corp., 137 S. Ct. at 739.
103 35 U.S.C. § 271(f)(1).
104 See generally Promega Corp. v. Life Technologies Corp., 773 F.3d at 1344-58.
105 Life Technologies Corp. v. Promega Corp., 136 S. Ct. 2505 (2016).
106
Petition
for
a
Writ
of
Certiorari,
SCOTUSBLOG
(June
11,
2017),
http://www.scotusblog.com/wp-content/uploads/2016/03/Life-Techs-Pet-App-14-1538.pdf.
107 Life Techs. Corp., 137 S. Ct. at 739. See generally, G. Edward Powell III, Note, Commodity
Supply and Extraterritorial Patent Infringement in Life Technologies v. Promega, 12 DUKE CON. L. &
PP SIDEBAR 163 (2017).
108 Life Techs. Corp., 137 S. Ct. at 739.
97
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argued.109
Starting
with
the
Patent
Act
itself,
“substantial” is not defined, and the dictionary meaning could go either way.110
Looking at the context of the subsection,111 “substantial” has a quantitative meaning,
as it modifies “of the components of a patented invention,”112 and is a workable
definition.113
The Court then had to decide if a single component could be a “substantial
component,” and examining again the text of the Patent Act, the Court decided that
“components” could not be a single component.114 Congress meant “components” to be
plural, and “component to be singular.115
Not joined by Justices Alito and Thomas in this portion only, the Court looked to
legislative history and concluded that their decision “comports with Congress’
intent.”116 Justice Alito’s concurrence further stated that any number of components
greater than one is not necessarily sufficient, only that more than one is required.117
This is an important opinion by the Supreme Court, both for what it states, and
what it does not. Specifically, the Court did not “consider how to identify the
‘components’ of a patent or whether and how that inquiry relates to the element of a
patent claim.”118 Further, the Court left open the issue of “how close to ‘all’ of the
components ‘a substantial portion’ must be.”119 Finally, no mention in the opinion
occurred for the presumption against extraterritoriality, although it was brought up
at oral argument.120 Again, these issues may be left for a later day.

Id.
Id.
111 35 U.S.C. § 271(f)(1).
112 Life Techs. Corp., 137 S. Ct. at 740. While Promega does not agree with the quantitative
definition, it also proposed a case specific approach, which the Court did not adopt, because it would
compound complexity.
113 Id. at 741.
114 Id. Looking at the next subsection, 35 U.S.C. § 271 (f)(2), this refers to “any component,” in the
singular sense.
115 Id. at 742. The Court discussed its holding in Microsoft Corp. v. AT&T Corp., 550 U.S. 437
(2007), which didn’t involve the number of components, but rather whether there was a component.
See generally, Sue Mota, MedImmune, Microsoft, and KSR: The U.S. Supreme Court in 2007 Tips the
Balance In Favor of Innovation in Patent Cases, and Thrise Reverses the Federal Circuit, 11 MARQ.
INTELL. PROP. L. REV. 181 (2007).
116 Life Techs. Corp., 137 S. Ct. at 742-43. Congress enacted this subsection after the Court’s
decision in Deepsouth Packing Co. v. Laitram Corp., 206 U.S. 518 (1972). The Court concluded that a
single component is outside the scope of the subsection.
117 Id. at 743.
118 Id.
119 Id. at 742.
120
Oral
Argument
Transcript,
at
12
(June
11,
2017),
available
at
https://www.supremecourt.gov/oral_arguments/argument_transcripts/2016/14-1538_j4ek.pdf.
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IV. SCA HYGIENE PRODUCTS V. FIRST QUALITY BABY PRODUCTS, LLC
Except as otherwise provided by law, no recovery shall be had for any
infringement committed more than six years prior to the filing of the
complaint or counterclaim for infringement in the action.121
Is laches a defense against infringement falling under the “except as otherwise
provided” clause above, during the six-year statute of limitation? The Court of Appeals
for the Federal Circuit said yes en banc in SCA Hygiene Products Aktiebolag v. First
Quality Baby Products, LLC.122 The United States Supreme Court, however, on March
21, 2017 vacated and remanded, seven to one, holding that laches may not be used as
a defense during the six-year patent statute of limitations.123
SCA Hygiene Products (hereinafter SCA) is a “leading global hygiene and forest
products company” founded in 1929 and headquartered in Stockholm, Sweden.124 First
Quality Baby Products, LLC, founded in New York in 20018, is a subsidiary of First
Quality Enterprises, and produces and markets baby care products.125 First Quality
Enterprises is a private corporation founded in New York in 1998.126 The parties each
offer a broad range of products, and compete in the toddler and adult disposable diaper
markets.
SCA is the original assignee of U.S. Patent No. 6,375,646 (the ‘646 patent) issued
in the U.S. in 2002 on a disposable absorbent pants-type diaper.127 SCA’s legal counsel
sent the President of First Quality Enterprises a letter in 2003 which stated in part,
“we suggest that you study” the ‘646 patent. “If you are of the opinion that the First
Quality Prevail All Nites absorbent pants-type diaper does not infringe any of the
claims of this patent, please provide us with and explanation as to why you believe
your products do not infringe.” Further, if First Quality believed that infringement
occurred, they needed to give assurances that the infringement would cease, and a
request a response in less than a month.128 On the requested reply-by date, First
Quality’s legal counsel responded in part that, “as you suggested, we studied” the ‘646
patent, and believed that a prior patent invalidated SCA’s patent, and further stated,
“as you know, an invalid patent cannot be infringed,” and directed all further
correspondence to the legal counsel.129

35 U.S.C. § 286.
807 F.3d 1311 (Fed. Cir. 2015).
123 SCA Hygiene Prod. Aktiebolag v. First Quality Baby Prod., LLC, 137 S. Ct. 954, 197 L. Ed. 2d
292 (2017).
124
SCA
at
a
Glance,
SCA
(last
visited
June
12,
2017)
available
at
http://www.sca.com/en/About_SCA/SCA_in_Brief/.
125 Company Overview of First Quality Baby Products, LLC, BLOOMBERG (last visited June 12,
2017) https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapid=61844136.
126
First Quality Enterprises, Inc., History (June 12, 2017) available at
http://www.firstquality.com/x167.php.
127 U.S. Patent No. 6,375,646, available at http://www.google.com/patents/US6375646.
128 SCA Hygiene Prod. Aktiebolag, 137 S. Ct. at 957-58.
129 Id. Four months later, in 2004, SCA sent another letter to First Quality alleging that another
SCA patent was infringed. First Quality replied that this patent’s claims were not infringed, and
repeated that correspondence should go to First Quality’s legal counsel.
121
122
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In 2004, SCA requested an ex parte reexamination of the ‘646 at the U.S. Patent
Office, concerning the patent which First Quality previously claimed to the `646 patent
and thus invalidated it. In 2007, the U.S. Patent Office issued a reexamination
certificate that not only confirmed the validity of all the ‘646 patent claims, but also
added dependent claims.130
In 2010, SCA filed this patent infringement suit, alleging that some of First
Quality Baby Products’ pants-type disposable diapers infringe on claims of SCA’s ‘646
patent.
First Quality counterclaimed alleging non-infringement and patent
invalidity.131 A Markman132 hearing was held. First Quality then moved for summary
judgment, arguing that SCA’s allegations were barred by laches and equitable
estoppel.133 Since SCA knew of its patent infringement claims against First Quality
in 2003 when they sent first letter, the district court granted First Quality’s motion for
summary judgment.134
SCA appealed, and in 2014 a panel of the Court of Appeals for the Federal Circuit
affirmed on the laches issue.135 In 2014, however, the U.S. Supreme Court decided the
copyright case Petrella v. Metro-Goldwyn-Mayer,136 that laches may not be used as a
defense during a copyright’s three-year statute of limitations. The appeals court en
banc held six to five that laches remains a defense in patent appeals cases.137 The
dissent would have applied Petrella in this patent case, and laches would not have been
a defense during the six years patent statute of limitations.138
SCA requested certiorari on the issue of whether or to what extent a defense of
laches applies during the six-year patent statute of limitations, and granted the writ
of certiorari in 2016.139 On March 21, 2017, the en banc decision of the Court of Appeals
for the Federal Circuit vacated and remanded the case, seven to one at the Supreme
Court, with Justice Breyer dissenting.140 Writing for the majority, Justice Alito
130 Id. SCA did not notify First Quality of this, nor did it tell First Quality that SCA intended to
file suit.
131 Id.
132 Markman v. Westview Instruments, Inc., 517 U.S. 370 (1996). See generally, Sue Mota,
Markman v. Westview Instruments, Inc. - The Supreme Court Unanimously Holds That Patent
Construction is Within the Exclusive Province of the Court Under the Seventh Amendment, 3
RICHMOND JOURNAL OF LAW AND TECHNOLOGY 3 (1997).
133 SCA Hygiene Prod. Aktiebolag, 137 S. Ct. at 960.
First Quality also moved for partial
summary judgment of non-infringement, among other things.
134 Id. at 972.
135 SCA Hygiene Prod. Aktiebolag v. First Quality Baby Prod., LLC, 767 F.3d 1339 (Fed. Cir.
2014). The panel, however, reversed on the equitable estoppel issue. Id. at 1350.
136 134 S. Ct. 1962 (2014). See generally, Jordyn Ostroff, Note, Petrella v. Metro-Goldwyn-Mayer,
Inc.: Is Equity Down for the Count?, 30 BERKELEY TECH. L. J. 965 (2015); Daniel Brainard, The
Remains of Laches in Copyright Infringement Cases: Implications of Petrella v. Metro-Goldwyn-Mayer,
14 J. MARSHALL. REV. INTELL. PROP. L. 432 (2015).
137 SCA Hygiene Prod. Aktiebolag v. First Quality Baby Prod., LLC, 807 F.3d 1311 (Fed. Cir.
2015). The panel’s opinion on equitable estoppel was reinstated. Id. at 1333. See generally, Madelyn
McCormick, Keeping Laches: The Loss of the Laches Defense in Copyright Infringement Cases Does
Not Mean Depriving Patent Attorneys of the Time-Honored Defense, 50 SUFFOLK U. LAW REV. 117
(2017).
138 Id. at 1342.
139 SCA Hygiene Prod. Aktiebolag v. First Quality Baby Prod., LLC, 137 S. Ct. 954, 197 L. Ed. 2d
292 (2017).
140 Id.
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stated that the Court’s reasoning in the Petrella141 copyright case that laches does not
apply during the three year copyright statute of limitations142 applies here, during the
six year patent statute of limitations.143 While statutes of limitations and laches both
protect against untimely claims, statutes of limitations are Congressionally set, and
should override judicial decisions made on a case-by-case basis.144 “Laches is a gapfilling doctrine, and where there is a statute of limitations, there is no gap to fill.”145
Looking to the Patent Act statute of limitations section,146 the copyright logic
works in this patent case, according to the majority.147 The Federal Circuit read the
Patent Act phrase “except as otherwise provided by law”148 to include a section of the
Patent Act listing defenses, but not laches.149 The appeals court cited cases decided
before the enactment of the Patent Act of 1952 to support this contention.150 “After
surveying the pre-1952 case law, we are not convinced that Congress . . . departed from
the general rule regarding the application of laches to damages suffered within the
time for filing suit set out in a statute of limitations.”151 Thus, laches may not be
applied within the statute of limitations period.152
Justice Breyer, while agreeing that consistency between copyright and patent law
by applying Petrella153 is the majority’s strongest argument, nonetheless dissented.154
Justice Breyer believes that Petrella came to the wrong decision, and started the Court
in the wrong direction, and would have upheld the en banc decision.155
V. TC HEARTLAND LLC V. KRAFT FOODS GROUP BRANDS LLC
Any civil action for patent infringement may be brought in the judicial
district where the defendant resides, or where the defendant has committed
acts of infringement and has a regular and established place of business.156

Petrella v. Metro-Goldwyn-Mayer, 188 L. Ed. 2d 979 (2014).
17 U.S.C. § 507(b).
143 SCA Hygiene Prod. Aktiebolag, 137 S. Ct. at 959.
144 Id. at 960, citing Petrella, 188 L. Ed. at 986.
145 Id.
146 35 U.S.C. § 286.
147 SCA Hygiene Prod. Aktiebolag, 137 S. Ct. at 960.
148 35 U.S.C. § 286.
149 35 U.S.C. § 282(b)(1) (2017), which states that, “the following shall be defenses involving the
validity or infringement of a patent and shall be pleaded: (1) noninfringement, absence of liability for
infringement or unenforceability.”
150 SCA Hygiene Prod. Aktiebolag, 137 S. Ct. at 963-64.
151 Id. at 966. The Court separately reviewed pre-1938 equity cases, pre-1938 law cases, and
cases after the merger of law and equity in 1938 and before 1952. The pre-1938 cases provide “minimal
support,” and the evidence after 1938 is “scant” to support this contention. Id. at *23. Other
arguments made by First Quality “do not require extended discussion.”
152 Id. at 967.
153 Petrella v. Metro-Goldwyn-Mayer, 188 L. Ed 2d 979 (2014).
154 SCA Hygiene Prod. Aktiebolag, 137 S. Ct. at 971.
155 Id. at 973.
156 28 U.S.C. § 1400(b).
141
142
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Where is the residence of a corporation, in terms of this section on where a patent
action may be brought? The U.S. Supreme Court on May 22, 2017 unanimously held,
eight to zero,157 in TC Heartland LLC v. Kraft Foods Group Brands LLC that a
corporation resides only in its state of incorporation under this statute section, which
is not amended by another provision,158 reversing and remanding the Court of Appeals
for the Federal Circuit.159
Kraft Foods Group (hereinafter, Kraft) is “one of the largest consumer packaged
food and beverage companies in North America and worldwide,” and initially
incorporated in Delaware in 1980, with its principal place of business in Illinois.160 TC
Heartland, hereinafter Heartland, is “a global leader in the production of liquid water
enhancers and is headquartered in, and produces product in, Indiana,161 and is a
competitor of Kraft in the flavored drink mix market.162 In 2014, Kraft sued Heartland
in district court in Delaware,163 alleging infringement of three of Kraft’s patents which
generally relate to packages and containers for shelf-stable flavored liquid beverage
concentrates.164
157 TC Heartland LLC, 137 S. Ct. at 1516. Justice Gorsuch took no part in this decision. Oral
argument took place on March 27, 2017.
Oral argument transcript, available at
https://www.supremecourt.gov/oral_arguments/argument_transcripts/2016/16-341_8njq.pdf. Justice
Gorsuch became sworn in on April 10, 2017, after oral arguments have occurred. Neil M. Gorsuch,
Supreme Court biographies, available at https://www.supremecourt.gov/about/biographies.aspx.
158 Kraft Foods Group Brands LLC v. TC Heartland, LLC, 2016 U.S. Dist. LEXIS 28318 (D. Del.,
Mar. 7, 2016).
159 TC Heartland LLC v. Kraft Foods Grp. Brands LLC, 137 S. Ct. 1514, 197 L. Ed. 2d 816 (2017).
160 U.S. SEC Annual Report, KRAFT FOODS GROUP, INC. 2013 (last visited June 15, 2017)
available
at
https://www.sec.gov/Archives/edgar/data/1545158/000154515814000003/krft10k122813.htm. In 2012, Kraft changed its name from Kraft Foods Global, Inc. to Kraft Foods Group,
Inc., and incorporated to Virginia. Id. After a spin-off in 2012, Kraft Foods Group, Inc. was an
independent publicly traded company. Id. Kraft and Heinz merged in 2015. The KraftHeinz Company
Announces the Successful Completion of the Merger, KRAFTHEINZ COMPANY, available at
http://news.kraftheinzcompany.com/press-release/finance/kraft-heinz-company-announcessuccessful-completion-merger-between-kraft-foods. KraftHeinz is again incorporated in Virginia,
with its principal place of business in Pennsylvania. U.S. SEC Form 10-Q, KRAFTHEINZ (May 4, 2017)
available at http://ir.kraftheinzcompany.com/secfiling.cfm?filingID=1637459-17-81&CIK=1637459.
161 About Heartland Food Products Group, HEARTLAND AND SWEETENERS (last visited June 15,
2017) available at http://www.heartlandsweeteners.com/about.html. Heartland also produces in the
Netherlands. Id.
162 TC Heartland LLC, 137 S. Ct. at 1517.
163 Of the 94 federal district courts, two, the district court of Delaware and the district court in
the eastern district of Texas, had nearly half of the 2013 patent cases filed. In fact, 56% of the cases
filed in the district court in Delaware were patent cases. Jonas Anderson, Court Competition for
Patent Cases, 163 U. PENN. L. REV. 631, 632 (2015). See also, Brian J. Love and James Yoon,
Predictively Expensive, A Critical Look at Patent Litigation in the Eastern District of Texas, 20 STAN.
TECH. L. REV. 1 (2017); Jonas Anderson, Judge Shopping in the Eastern District of Texas, 48 LOY. U.
CHI. L. J. 539 (2016).
164 Kraft Foods Group Brands LLC v. TC Heartland, LLC, 2016 U.S. Dist. LEXIS 28318 (D. Del.
Mar. 7, 2016). U.S. Patent No. 8,293,299 relates to containers and methods for dispensing multiple
doses of a concentrated liquid, and shelf stable concentrated liquids. U.S. Pat. No. 8,293, 299,
available at http://www.google.com/patents/US8293299. U.S. Patent No. 8,603,557 is also for
containers and methods for dispensing multiple doses of a concentrated liquid, and shelf stable
concentrated
liquids.
U.S.
Pat.
No.
8,603,299,
available
at
http://www.google.com/patents/US8603557. U.S. Patent 8,5111,472 relates to containers having
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Defendant Heartland moved to dismiss for lack of personal jurisdiction because
Heartland did not reside in Delaware, and Heartland did not have an established place
of business in Delaware,165 and Heartland requested a transfer of venue to a district
court in Indiana; the district court in Delaware denied the motion to dismiss.166
Heartland’s unsuccessful arguments at the district court level also included that only
2% of its product shipped into Delaware, and that the Delaware district court should
not address the out of state alleged infringement. The district court observed that if
this novel jurisdiction theory that 98% of its sales were not in Delaware were adopted
by the court, it would result in “sweeping changes to the way patent litigation proceeds
in the United States.”167 Heartland also argued168 that venue in a patent case is only
in the defendant’s state of incorporation, or where the defendant has committed acts
of infringement and has a regular place of business, citing 28 U.S.C. § 1400(b),169 and
that amendments by Congress in 2011 changed patent venue,170 and thus Delaware is
not the appropriate venue for this litigation. The district court disagreed, and also
thus denied transfer of the case.171
Heartland then requested that the Court of Appeals for the Federal Circuit issue
a writ of mandamus to the Delaware district court to dismiss or transfer Kraft’s patent
infringement case. The appeals court denied the request in 2016.172 Calling a writ of
mandamus an “extraordinary remedy appropriate only in exceptional
circumstances,”173 the Federal Circuit followed its own precedent, thus in this author’s
opinion inviting reversal, and denied the writ.174
On December 14, 2016, the U.S. Supreme Court granted Heartland’s petition for
a writ of certiorari, on the issue of whether 28 U.S.C. § 1400(b) is the sole and exclusive
patent jurisdiction statute, unencumbered by 28 U.S.C. § 1391(c).175 On May 22, 2017,
the Supreme Court unanimously reversed the Court of Appeals for the Federal Circuit
and remanded.176
Writing for the Court, Justice Thomas started with the specific patent venue
statute, 28 U.S.C. § 1400(b),177 which states, as above, that the proper district is where
shrink wrap sleeves. U.S. Pat. No. 8,511,472, available at http://www.google.com/patents/US8511472.
The original assignee for all three is Kraft Foods Group Brands, LLC.
165 28 U.S.C. § 1400(b).
166 Kraft Foods Group Brands, LLC. v. TC Heartland LLC, No. 14-28-LPS, 2015 Dist. LEXIS
106515 (D. Del. Aug. 13, 2015).
167 Id. at *3-4.
168 Id. at *21.
169 28 U.S.C. § 1400(b).
170 28 U.S.C. § 1391 (2017).
171 Kraft Foods Group Brands, LLC. v. TC Heartland LLC, No. 14-28-LPS, 2015 Dist. LEXIS
106515 at *41 (D. Del. Aug. 13, 2015).
172 Kraft Foods Group Brands, LLC. v. TC Heartland, LLC, 821 F.3d 1338 (Fed. Cir. 2016).
173 Id. at 1341.
174 Id. at 1345. See generally, Bryan L. Frye and Christopher J. Ryan, Jr., Fixing Forum Selling,
25 U. MIAMI BUS. L. REV. 1 (2016-17); Ana Santos Rutschman, Patent Venue Exceptionalism after TC
Heartland v. Kraft, 25 U. MIAMI BUS. L. REV. 29 (2016-17); Richard Samp, TC Heartland: The Patent
Venue Question is Informed by Personal Jurisdiction Issues, 25 U. MIAMI BUS. L. REV. 45 (2016 -17).
175 TC Heartland LLC v. Kraft Food Brands Grp., 137 S. Ct. 614 (2016).
176 See generally TC Heartland v. Kraft Foods Grp. Brands LLC, 137 S. Ct. 1514, 197 L. Ed. 2d
816 (2017).
177 Id. at 1516.
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the defendant resides, and instead could be where the defendant has allegedly
committed infringing acts and has a regular established place of business. Justice
Scalia then addressed, under this statute, the district where a domestic corporation
resides.178 The Supreme Court in 1957 in Fourco Glass Co.v. Transmirra Products
Corp.179 held that a domestic corporation resides only in its state of incorporation. The
Court in Fourco rejected the argument that the specific patent venue statute180 is
modified by the general corporate residence statute section.181 The former specific
section has not been modified since Fourco, but the latter general section has been
subsequently modified twice.182 The Court concluded that these modifications of the
general statute do not affect the specific patent venue statute as interpreted in Fourco,
and thus the ruling stands, that a domestic corporation resides only in the
incorporation state.183 The appeals court reversed, holding that the amendments of
the general statute did also amend the specific patent venue statute as interpreted in
Fourco.184
In reaching this conclusion, Justice Thomas reviewed the predecessor of the 1948
specific patent venue statute, as well as subsequent to its enactment, leading up to
Fourco, which stated that Congress intended 28 U.S.C. § 1400(b) to be “complete,
independent and alone controlling in its sphere.”185 When Congress amended the
general statute in 1988 and again in 2011, Congress did not alter the specific patent
venue statute.186 Addressing the issue of whether Congress changed the specific
section when modifying the general, Justice Thomas cited the late Justice Scalia and
Garner’s book, which states, “A clear, authoritative judicial holding on the meaning of
a particular provision should not be cast in doubt and subjected to challenge whenever
a related though not utterly inconsistent provision is adopted in the same statute or
even in an affiliated statute.”187
Justice Thomas started the opinion framing the issue as where a patent
infringement lawsuit should be brought, against a domestic corporation.188 Whether
Heartland is or is not a corporation for purposes of this section is left for remand.189
The Court did not address the issue of what is the proper district for non-corporations,
nor the issue of the appropriate district for foreign corporations,190 and again, is left
for another case.

Id.
353 U.S. 222, 226 (1957).
180 28 U.S.C. § 1400(b).
181 28 U.S.C. § 1391(c).
182 See TC Heartland LLC, 137 S. Ct. at 1516-17.
183 Id.
184 Id. at 1517.
185 Id. at 1519 citing Fourco, 353 U.S. at 228.
186 Id. at 1519-20.
187 Id. at 1520, citing A. Scalia and B. Garner, READING LAW 331 (2012).
188 TC Heartland v. Kraft Foods Grp. Brands LLC, 137 S. Ct. 1514, 197 L. Ed. 2d 816 (2017).
189 Id. at note 1.
190 Id. at note 2.
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VI. IMPRESSION PRODUCTS, INC. V. LEXMARK INT’L., INC.
Except as otherwise provided in this title, whoever makes, uses, offers to sell,
or sells any patented invention, in the United States or imports into the
United States any patented invention during the term of the patent therefor,
infringes the patent.191
But, once that first sale is made, does the patent holder have rights which
continue under patent law, or are those rights exhausted? The U.S. Supreme Court
on May 30, 2017 ruled eight to zero that the patent holder’s rights are exhausted under
patent law with the first sale in the U.S., and seven to one, with Justice Ginsburg
dissenting, that this first sale exhausts a patent holder’s right in international first
sales in Impression Products, Inc. v. Lexmark International, Inc.192
Lexmark International, Inc. (hereinafter Lexmark) is a publicly traded company
founded in 1991, and is headquartered in Lexington, Kentucky.193 Lexmark has
become a “leading developer, manufacturer and supplier of printing, imaging,” and
other devices such as printer toner cartridges.194 Lexmark holds a number of patents
on its printer cartridges.195 Impression Products, Inc. (hereinafter Impression
Products) founded in 1979, and since the early 1990’s, “bought used printer cartridges,
refurbished them, and resold them.”196 Lexmark’s printer cartridges were sold
domestically and abroad. All of the domestic, and some of the foreign, printer cartridge
sales included a printer cartridge single use/no resale user agreement under which the
user, who was told they were buying the cartridge at a discount, agreed to a single use
and only return the cartridge to Lexmark and not have it refilled elsewhere.197
Impression Products obtained, refilled, and sold in the U.S. Lexmark printer
cartridges, and also obtained Lexmark cartridges abroad and imported them into the
U.S.198
Lexmark sued Impression Products199 for patent infringement under 35 U.S.C.
§ 271.200 The district court held that Lexmark’s patent infringement claims were

191 35 U.S.C. § 271(a). There is nothing “otherwise provided in the Patent Act.” Lexmark Int’l.,
Inc. v. Impression Products, Inc., 816 F. 3d. 721, 726 (Fed. Cir. 2016).
192 137 S. Ct. 1523, 198 L. Ed. 2d 1 (2017).
193
Lexmark,
Company
Overview,
LEXMARK
(June
16,
2017),
available
at
http://www.lexmark.com/en_us/about/company.html.
194 Lexmark U.S. SEC Form 10-K, Item 1, Business (Feb. 29, 2016).
195 Lexmark Int’l., Inc. v. Impression Products, Inc., 816 F. 3d. 721, 727 (Fed. Cir. 2016).
Impression Products did not dispute the validity or enforceability of Lexmark’s patents. Id. at 729.
196 Robb Mandelbaum, Small Business Challenges Printing Giant Lexmark in Supreme Court
Patent
Dispute,
FORBES
(Nov.
22,
2016),
https://www.forbes.com/sites/robbmandelbaum/2016/11/22/small-business-challenges-printing-giantlexmark-in-supreme-court-appeal/#5f8e73f66aba.
197 Lexmark Int’l., Inc., 816 F. 3d. at 727. Lexmark sells directly to end users, and to resellers.
198 Id.
199 Id. at 728. Lexmark also sued others, but at the time of litigation, Impression Products was
the only company left as a defendant.
200 Id. Lexmark sued under 35 U.S.C. § 271(a) for direct patent infringement, and under 35 U.S.C.
§ 271(c) for contributory infringement, for the few cartridges which only the end user infringes.
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barred by the patent doctrine of exhaustion, and “must be dismissed.”201 The district
court reviewed the first patent exhaustion case decided by the Supreme Court in 1853,
Bloomer v. McQuewan,202 which held that when the patented item comes into the
hands of the purchaser, it is no longer subject to the patent monopoly, and is the
purchaser’s personal property, not protected by federal law, but by state law.203 In
2008, the Supreme Court decided Quanta Computer, Inc. v. LG Electronics, Inc.,204
which stated that “the authorized sale of an article that substantially embodies a
patent exhausts the patent holder's rights and prevents the patent holder from
invoking patent law to control post sale use of the article.”205 Consequently, the sale
of the printer cartridges by Lexmark to consumers “took the cartridges outside the
scope of the patent monopoly” and Lexmark couldn’t use patent law to hold First
Impression liable.206 The district court stated that this is consistent with Quanta, and
to hold otherwise would be confusing for consumers, granted Impression Products’
motion to dismiss, and Lexmark’s patent infringement claims against Impression
Products on the domestic return printer cartridges were dismissed.207 Both parties
appealed.
The Court of Appeals for the Federal Circuit heard the appeal en banc, to consider
whether two decisions of the appeals court remained valid in light of subsequent
Supreme Court decisions.208 On both issues, the domestic sales as well as the
international sales, the Court of Appeals started its analysis with its own
precedents,209 which in hindsight, wasn’t the best starting point. According to Chief
Justice Roberts, writing for the Court, the Federal Circuit “got off on the wrong foot.”210
The Court of Appeals for the Federal Circuit reconfirmed its 1992 decision in
Mallinckdrodt, Inc. v. Medipart, Inc.211 even in light of the Supreme Court’s 2008
decision in Quanta.212 The appeals court also reconfirmed its 2001 decision in Jazz
Photo Corp. v. International Trade Commission213 in light of the Supreme Court’s 2013
201 Lexmark Int’l., Inc. v. Ink Technologies Printer Supplies, LLC, No. 1-10:CV-564, 2014 U.S.
Dist. LEXIS 41045 at *8 (S.D. Ohio March 27, 2014).
202 Id. citing 55 U.S. 539, 549 (1853).
203 Id. citing 55 U.S. 549-50 (1853). The district court further cited the next Supreme Court
precedent on patent exhaustion, General Talking Pictures Corp. v. Western Electric, Co., 304 U.S. 175
(1938), which held that since the patent licensee sold the patent product beyond the patent license
scope, the doctrine of patent exhaustion did not apply. Id. citing 304 U.S. at 181.
204 553 U.S. 617 (2008).
See generally Sue Mota, The Doctrine of Patent Exhaustion: Not
Exhausted by the Supreme Court in 2008 in Quanta Computer v. LG Electronics, XI SMU SCI. & TECH.
L. J. 337 (2008).
205 Quanta, 553 U.S. at 618.
206 Lexmark Int’l., Inc. v. Ink Technologies Printer Supplies, LLC, No. 1-10:CV-564, 2014 U.S.
Dist. LEXIS 41045 at *24 (S.D. Ohio March 27, 2014).
207 Id. at *23-24.
208 Lexmark Int’l., Inc. v. Impression Products, Inc., 816 F. 3d. 721, 726 (Fed. Cir. 2016).
209 Id. at 726-27.
210 Impression Products, Inc. v. Lexmark Int’l., Inc., No. 15-1189, 2017 U.S. LEXIS 3397 at *14
(U.S. May 30, 2017).
211 976 F.2d 700 (Fed. Cir. 1992).
212 553 U.S. 617 (2008). The district court had ruled that Quanta overruled Mallinckdrodt by its
silence. Lexmark Int’l., Inc. v. Impression Products, Inc., 816 F. 3d. 721, 730 (Fed. Cir. 2016).
213 264 F.3d 1064 (Fed. Cir. 2001). The district court did not hold that Kirtsaeng overruled Jazz
Photo Corp. Lexmark Int’l., Inc. v. Impression Products, Inc., 816 F. 3d. 721, 730 (Fed. Cir. 2016).
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copyright decision in Kirtsaeng v. John Wiley & Sons, Inc.214 “Mallinckdrodt has been
the governing case law since 1992 and has been reiterated in subsequent precedent,”
according to the Federal Circuit,215 and the majority saw no reason not to apply it to
allow Lexmark to use legal restrictions on downstream use of the printer cartridges.216
For the sales abroad, the appeals court concluded, as it did in Jazz Photos, that U.S.
rights are not waived in foreign sales.217 Kirtsaeng does not apply, according to the
Federal Circuit, because patent cases have their own considerations.218 A restriction
such as Lexmark placed does not exhaust downstream uses by the purchaser, and thus
the Federal Circuit upheld the district court’s ruling of non-exhaustion on the
international sales, and reversed the district court’s ruling of exhaustion on U.S.
sales.219
Judge Dyk, joined by Judge Hughes, dissented.220 Concerning Mallinckdrodt,
Judge Dyk stated, “we exceed our role as a subordinate court by declining to follow the
explicit domestic exhaustion rule announced by the Supreme Court,”221 and would
overrule Mallinckdrodt.222 Further, concerning Kirtsaeng and other Supreme Court
precedent, “The majority’s justifications for refusing to follow Supreme Court authority
establishing the exhaustion rule misconceive our role as a subordinate court,”223 and
would have overruled Jazz Photos’ blanket ban on international patent exhaustion.224
The U.S. Supreme Court granted the writ of certiorari on December 2, 2016225 on
the two issues of domestic and international patent exhaustion, in light of Kirtsaeng.226
and on May 30, 2017, the Supreme Court reversed eight to zero holding that Lexmark
exhausted its patent rights on U.S. sales, and reversed seven to one with Justice
Ginsburg dissenting, that Lexmark exhausted its patent rights on international sales,
and remanded.227
Chief Justice Roberts, writing for the majority, started with the domestic sales,
and concluded that Lexmark exhausted its patent rights in these cartridges the

214 133 S. Ct. 1351 (2013). See generally, Dustin M. Knight, Comment, Lost in Translation: How
Practical Considerations in Kirtsaeng Demand International Exhaustion in Patent Law, 50 U. RICH.
L. REV. 1333 (2016).
215 Lexmark Int’l., Inc. v. Impression Products, Inc., 816 F. 3d. 721, 752 (Fed. Cir. 2016).
216 Id. at 753.
217 Id. at 754.
218 Lexmark Int’l., Inc. v. Impression Products, Inc., 816 F. 3d. 721, 758 (Fed. Cir. 2016).
219 Id. at 774. See generally John F. Duffy and Richard M. Hynes, Common Law versus Statutory
Bases of Patent Exhaustion, 103 VA. L. REV. ONLINE 1 (2017); Daniel J. Hemel and Lisa Larrimore
Oullette, Trade and Tradeoff: The Case of International Patent Exhaustion, 116 COLUM. L. REV.
SIDEBAR 17 (2016).
220 Lexmark Int’l., Inc. v. Impression Products, Inc., 816 F. 3d. 721, 774 (Fed. Cir. 2016).
221 Id. In this author’s opinion, the dissent appropriately understands the role of the appeals
court.
222 Id. at 788.
223 Id. at 780. Unlike the majority, the dissent states that Kirtsaeng cannot be dismissed, just
because it is a copyright case. Id. at 786.
224 Id. at 788.
225 Impression Products, Inc. v. Lexmark International, Inc., 137 S. Ct. 546 (2016).
226 133 S. Ct. 1351 (2013).
227 Impression Products, Inc. v. Lexmark Int’l., Inc., No. 15-1189, 2017 U.S. LEXIS 3397 (U.S.
May 30, 2017).
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moment it sold them.228 While the contracts with end purchasers may be legal under
contract law, they may not be used by Lexmark to retain patent rights, according to
all eight voting members of the Court.229 According to the Court, for over 160 years
since the Court’s ruling in Bloomer v. McQuewan,230 the doctrine of patent exhaustion
has automatically limited the exclusive right of the patent holder to sell that particular
item, and granted a personal property right to the owner.231 This “venerable principle”
was “dismissively viewed” by the majority of the Federal Circuit, according to the
Court.232 Chief Justice Roberts then gave a very practical example of a shop that
restores and sells used cars; the “smooth flow of commerce would sputter if companies
that made the thousands of parts which go into a vehicle could keep their patent rights
after the first sale.”233 The Court examined its precedent including Quanta234 and
stated that the long line of precedent “allows for only one answer.”235 Lexmark may
not sue Impression Products under patent infringement law, but may turn to contract
law.236 The Court summarized, “patent exhaustion is uniform and automatic. Once a
patentee decides to sell--whether on its own or through a licensee--that sale exhausts
its patent rights, regardless of any post-sale restrictions the patentee purports to
impose, either directly or through a license.”237 Thus, the Court of Appeals for the
Federal Circuit reversed the domestic sales issue by all eight voting members of the
Court.
Moving to the international sales, seven of the Court’s voting members agreed
that “an authorized sale outside the United States, just as one within the United
States, exhausts all rights under the Patent Act.”238 The majority examined the first
sale under copyright law239 and the Court’s copyright precedent in Kirtsaeng v. John
Wiley & Sons, Inc.240 Interestingly, the Court turned to its own precedent under
copyright law twice this term, in Lexmark, and previously in SCA Hygiene Products v.
First Quality Baby Products.241 Just as the first sale doctrine was straightforward in
international sales of copyrighted goods, “applying patent exhaustion to foreign sales
is just as straightforward.”242 The Court distinguished its prior international patent
exhaustion decision in 1890, Boesch v. Graff,243 because the patentees in Graff hadn’t
Id. at *12.
Id.
230 55 U.S. 539 (1853).
231 Impression Products, Inc. v. Lexmark Int’l., Inc., No. 15-1189, 2017 U.S. LEXIS 3397 at *18
(U.S. May 30, 2017).
232 Id. at *13.
233 Id.
234 Quanta Computer, Inc. v. LG Electronics, Inc., 553 U.S. 617, 638 (2008).
235 Impression Products, Inc. v. Lexmark Int’l., Inc., No. 15-1189, 2017 U.S. LEXIS 3397 at *14
(U.S. May 30, 2017).
236 Id.
237 Id.
238 Id. at *17.
239 17 U.S.C. § 109(a).
240 568 U.S. 519, 525 (2013).
241 SCA Hygiene Products Aktiebolag v. First Quality Baby Products, LLC. No. 15-927, 2017 U.S.
LEXIS 2023 (U.S. March 21, 2017).
242 Impression Products, Inc. v. Lexmark Int’l., Inc. No. 15-1189, 2017 U.S. LEXIS 3397 at * 17
(U.S. May 30, 2017).
243 133 U.S. 697 (1890).
228
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exhausted their patent rights because they hadn’t sold them. The Court rejected a
middle approach suggested by the United States as amicus, that patent rights are
exhausted unless reserved,244 because “restrictions and location are irrelevant.”245
Thus, reversing the Federal Circuit on both issues.246
Justice Ginsburg dissented on the second international issue, because a U.S.
patent does not confer rights abroad.247 Justice Ginsburg also dissented in Kirtsaeng
on the issue of international first sale under copyright law.248
This decision is bound to cause numerous changes in the global and domestic
supply chain across many sectors. Companies will have to adjust to avoid refurbishing,
re-importation, and arbitrage involving their products. Chief Justice Roberts pointed
out that Lexmark’s contracts were with the direct-sale customers, not with Impression
Products,249 and further, that these contracts may be valid and enforceable.250 One
possible solution for the many companies grappling with this issue post-Lexmark is to
be sure to have such restrictions in all contracts, and enforce them with the other
parties to the contract. Of course, this is a much more difficult enforcement issue due
to the many end-users, rather than dealing directly with a company such as Impression
Products, who now is not reachable under patent exhaustion, and further doesn’t have
a contract with a patent holder such as Lexmark.
VII. SANDOZ INC. V. AMGEN INC.
It shall be an act of infringement to submit (C)(i) with respect to a patent which is identified in . . . an application seeking
approval of a biologic product, or (ii) if the applicant . . . fails to provide the
application and information required, . . . if the purpose for such submission
is to gain approval under such act to engage in the commercial manufacture,
use, or sale of a drug, veterinary biological product, or biological product
claimed in a patent, or the use of which is claimed in a patent before the
expiration of such patent.251
The U.S. Supreme Court on June 12, 2017, held nine to zero in Sandoz Inc. v.
Amgen Inc., the only patent case decided this term with a full Court, that a biological
biosimilar applicant may not be forced by injunction to comply with the procedure of
giving the reference product manufacturer twenty day notice of the biosimilar FDA
application spelled out in the Biologics Price Competition and Innovation Act (BPCIA),
244 Impression Products, Inc. v. Lexmark Int’l., Inc. No. 15-1189, 2017 U.S. LEXIS 3397 at *19
(U.S. May 30, 2017).
245 Id. at *20.
246 Id.
247 Id.
248 Id. at *21.
249 Impression Products, Inc. v. Lexmark Int’l., Inc. No. 15-1189, 2017 U.S. LEXIS 3397 at *10
(U.S. May 30, 2017).
250 Id. at *12.
251 35 U.S.C. § 271(e)(2) (2017).
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and that under the BPCIA, the biological biosimilar applicant may give the reference
product sponsor the required 180 day notice of commercial marketing, before the
biosimilar producer gets the FDA license.252 The Court of Appeals for the Federal
Circuit vacated, reversed, and remanded the case.253
Amgen, one of the world’s leading biotechnology companies,254 originated in
California in 1980, and went public in 1983.255 In 1991, the FDA approved Amgen’s
drug, Filgrastim,256 a bone marrow stimulant which can help the body make white
blood cells, which Amgen sold under the brand name Neupogen. Sandoz, a division of
Norvartis, is “a global leader in generic and biosimilar medicines.”257
Congress passed the complex Biologics Price Competition and Innovation Act
(BPCIA) as part of the Patient Privacy and Affordable Care Act, signing the Act into
law in March of 2010.258 A biologic is a “type of drug derived from natural, biological
sources such as animals or microorganisms.”259 The BPCIA gives producers of biologic
products260 which are biosimilar261 to the reference product already on the market with
an FDA license, an abbreviated pathway to approval,262 and also gives ways and times
in that process to resolve patent disputes.263 The biosimilar applicant may not apply
until four years after the FDA has licensed the original reference product sponsor, and
the FDA may not approve a biologic biosimilar application until twelve years after the
approval of reference product sponsor’s license.264 Within twenty days of being notified
by the FDA that the application for a biosimilar product has been received, the
biosimilar producer “shall” provide the reference product’s sponsor with the
application and other material provided.265 This notice within twenty days triggers an
“artificial” act of infringement (because a traditional act of infringement hasn’t yet
occurred),266 for which there are remedies of damages and injunctive relief.267 Within
sixty days of this notice, the reference product sponsor is to give a list of patents which

252

2017).

Sandoz Inc. v. Amgen Inc., Nos. 15-1039 and 1195, 2017 U.S. LEXIS 3723 (U.S. June 12,

Id.
Amgen, About, http://www.amgen.com/about/ (last visited June 18, 2017).
255 Amgen, History, http://www.amgenhistory.com/ (last visited June 18, 2017).
256 Id.
257 Sandoz, Who We Are, https://www.sandoz.com/about-us/who-we-are (last visited June 18,
2017).
258 BPCIA, Title VII, Subtitle A, PPACA, which amends 42 U.S.C. § 262.
259 Sandoz Inc. v. Amgen Inc., Nos. 15-1039 and 1195, 2017 U.S. LEXIS 3723 at *9 (U.S. June
12, 2017).
260 42 U.S.C. § 262(i)(1) defines biologic product as a virus, therapeutic serum, toxin, antitoxin,
blood, blood derivative or component, among others, applicable to the prevention, treatment, or cure
of a disease of humans.
261 42 U.S.C. § 262(i)(2) defines biosimilarity as highly similar to the reference product with only
minor differences in clinically inactive components, and no clinically meaningful differences in the
biosimilar product from the reference product in safety, purity, and potency.
262 42 U.S.C. § 262(k).
263 35 U.S.C. § 271(e).
264 42 U.S.C. § 262(K)(7)(A), (B) (2017).
265 42 U.S.C. § (l)(2).
266 35 U.S.C. § 271(e)(2)(c)(i), (ii).
267 35 U.S.C. § 271(e)(4).
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may be infringed, and also a list of which patents, if any, the sponsor would license.268
Then, the applicant has sixty days to respond, giving any other patents which the
applicant deems relevant, discussing why the applicant believes it might not infringe,
and responding to the licensure issue.269 Then the sponsor has sixty days to respond
back about validity, enforceability, and infringement of each patent.270 The parties
then proceed to the first stage of litigation, on the patents they both agree to litigate,
or if they don’t agree, the patents in a simultaneous list exchange.271 This is the first
stage of patent litigation.
The second stage of patent litigation involves patents not litigated in the first
phase, and neither party may sue the other for a declaration of infringement, validity,
or enforcement of any non-litigated patent prior to the date that notice of commercial
marketing is received.272 This notice of commercial marketing is to be given by the
biosimilar producer no later than 180 days before the first commercial marketing of
the biosimilar product.273 But, if the biosimilar producer does not engage in this socalled patent dance, then the reference product sponsor, but not the biosimilar
producer, may bring an action for declaration of infringement, validity, or enforcement
of any patent without waiting for notice of commercial marketing.274 If the biosimilar
producer does engage in the patent dance, then after the notice of first commercial
marketing and before the first commercial marketing, the reference product sponsor
may request a preliminary injunction against the biosimilar producer on the validity,
enforcement, and infringement of any involved patent.275
On July 7, 2014, Sandoz got notice that the FDA accepted its application to make
Filagrastim.276 The next day, Sandoz mailed Amgen a letter offering conditional access
to the application, and stating that it anticipated FDA approval in first or second
quarter 2015, and it would start marketing immediately upon approval. On July 25,
2014, Amgen received a second letter, announcing intention to not follow the
procedural “dance,” or allow the full access and subsequent back-and-forth; Amgen
should sue for patent infringement to obtain information.277
Not surprisingly, on October 24, 2014, Amgen sued Sandoz for patent
infringement for claims of U.S. Patent No. 6,162,427 (the ‘427 patent),278 as well as
under California unfair competition law,279 and requested a preliminary injunction.280
Sandoz counterclaimed, including alleging both non-infringement and invalidity of the
42 U.S.C. § 262(l)(3)(A)(i), (ii).
42 U.S.C. § 262(l)(3)(B)(i), (ii), (iii) (2017).
270 42 U.S.C. § 262(l)(3)(C).
271 42 U.S.C. § 262(l)(4), (5).
272 42 U.S.C. § (l)(9)(A).
273 42 U.S.C. § (l)(8)(A).
274 42 U.S.C. § (l)(9)(B) (2017).
275 42 U.S.C. § (l)(8)(B).
276 Amgen Inc. v. Sandoz Inc., No. 14-cv-04741-RS, 2015 Dist. LEXIS 34537 at *10 (N.D. Cal.
March 15, 2015).
277 Id.
278 U.S. Patent No. 6,126,427 relates to the combination of G-CSF with a chemotherapeutic agent
for stem cell mobilization.
279 Amgen Inc. v. Sandoz Inc., No. 14-cv-04741-RS, 2015 Dist. LEXIS 34537 at *11 (N.D. Cal.
March 15, 2015).
280 Id. at *4.
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‘427 patent, and requested declaratory judgment that its conduct was permissible and
within the BPCIA.281
In its analysis, the district court analyzed the BPCIA process and the failure to
provide Amgen all required documentation within 20 days; the district court observed
that the “shall” language of the statute “does not imply it is mandatory in all
contexts.”282 If Sandoz had complied, it would have enjoyed a “temporary safe harbor
from litigation,”283 but, “perhaps confident in its limited exposure to liability and eager
to resolve patent disputes so as to not delay market entry,”284 and this decision by
Sandoz was permissible, according to the district court.285 It was also permissible for
Sandoz to give its 180-day notice prior to FDA approval.286 Thus, Sandoz did not
violate the BPCIA, according to the district court, and further, Amgen’s claims against
Sandoz under California state law were also dismissed with prejudice.287 The Court
dismissed Amgen’s motions for partial summary judgment or, in the alternative,
partial judgment on the pleadings, as well as its request for preliminary injunction.288
The decision was, of course, appealed, and in the first appellate decision289 on the
BPCIA, the Court of Appeals for the Federal Circuit in 2015 ruled that Sandoz did not
violate the BPCIA by not initially giving Amgen access to their FDA application and
relevant information.290 The appeals court, however, did reverse the district court on
the issue of when notice of commercial marketing may be given, which is only after
FDA approval, according to the appeals court.291 Since Sandoz gave Amgen another
notice of commercial marketing when the FDA approved Sandoz’s application on
March 6, 2015,292 this is the notice which counts under the BPCIA, according to the
appeals court, and Sandoz would be allowed to market its biosimilar 180 days after
that, on September 2, 2015.293 Amgen’s injunction pending appeal denied by the
district court but reversed and granted by the appeals court extended to September 2,
2015.294 The Federal Circuit affirmed the dismissal of the California state claims.295
The U.S. Supreme Court granted the writs of certiorari on the two issues under
the BPCIA of whether the “shall” language requires the biosimilar applicant to provide
Id.
Id. at *17.
283 Id.
284 Amgen Inc., at *20-21.
285 Id. at *21.
286 Id. at *25.
287 Id. at *28.
288 Id. at *33-34.
289 Amgen Inc. v. Sandoz Inc., 794 F.3d 1347, 1350 (Fed. Cir. 2015). See generally, Jon Tanaka,
“Shall” We Dance? Interpreting the BPCIA’s Patent Provisions, 31 BERKELEY TECH. L. J. 659 (2016);
Carl J. Minniti III, Sandoz v. Amgen: Why Current Interpretation of the Biologic Price Competition
and Innovation Act of 2009 is Flawed and Jeopardizes Future Competition, 97 J. PAT. & TRADEMARK
OFF. SOC’Y. 172 (2015).
290 Amgen, 794 F.3d at 1356.
291 Id. at 1358.
292 Id. at 1353.
293 Id. at 1360.
294 Id. at 1362.
295 Amgen, at 1360. Judge Newman dissented in part, on the issue of not requiring Sandoz to
follow the BPCIA procedure. Id. at 1366. Judge Chen dissented in part, on the issue of the injunction
pending appeal, and would dissolve the injunction. Id. at 1371.
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the application and relevant notice within twenty days to the reference product
sponsor, and whether the 180-day commercial marketing notice may be given before
FDA approval.296
On June 12, 2017, the full Supreme Court unanimously held that failure to give
the twenty day notice under the BPCIA by the applicant is not enforceable by
injunction, and the 180-day notice may be given before FDA approval, both vacating
and reversing the Court of Appeals for the Federal Circuit and remanding.297 Again
writing for the Court, Justice Thomas stated that the Court agreed with the Federal
Circuit that an injunction is not available to enforce the “patent dance,”298 but for a
different reason than the appeals court gave.299 The Supreme Court concluded that
Sandoz’s failure to disclose the required information within twenty days of its FDA
application is not an artificial act of infringement, which could be remedied by an
injunction.300 The remedy for an applicant such as Sandoz which fails to give the
required information is that the reference product sponsor may bring an action for
declaration of infringement,301 not an injunction. The action for declaration of
infringement excludes all other remedies, according to the Court.302 Congress did
include an injunction in the BPCIA for breach of confidentiality in the process,303 so
the Court concluded that Congress, if they desired, could also have included an
injunction as a remedy for an applicant who fails to engage in the initial BPCIA
process.304 So, according to the Court, the appeals court correctly denied the
injunction, but for the wrong reason. On remand, the Federal Circuit considered
whether Sandoz’s action constituted illegality under state law and then determine if
the BPCIA preempted state law, or just assume that California law provided remedy
and consider the preemption issue.305
Turning to the issue of the timing of the 180-day notice of commercial market, the
Supreme Court held that the 180-day notice did not have to be given only after FDA
licensure of the biosimilar biologic product, reversing the Court of Appeals for the
Federal Circuit which held that this notice could only come after FDA licensure.306
While the licensure must exist before the first commercial marketing, licensure isn’t
required before giving the notice.307 Thus, the Federal Circuit’s incorrectly decided to

296
297

2017).

Sandoz Inc. v. Amgen Inc., 137 S. Ct. 808 (2017).
Sandoz Inc. v. Amgen Inc., Nos. 15-1039 and 1195, 2017 U.S. LEXIS 3723 (U.S. June 12,

42 U.S.C. § 262(l)(2)(A).
Sandoz Inc. v. Amgen Inc., Nos. 15-1039 and 1195, 2017 U.S. LEXIS 3723 at *21 (U.S. June
12, 2017).
300 Id. at *22.
301 42 U.S.C. § 262(l)(9)(B).
302 Sandoz Inc. v. Amgen Inc., Nos. 15-1039 and 1195, 2017 U.S. LEXIS 3723 at *25 (U.S. June
12, 2017).
303 42 U.S.C. § 262(l)(1)(H) (2017).
304 Sandoz Inc. v. Amgen Inc., Nos. 15-1039 and 1195, 2017 U.S. LEXIS 3723 at *26 (U.S. June
12, 2017).
305 Id. at *28-29.
306 Id. at *29.
307 Id.
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keep the injunction until 180 days after licensure, according to the Court, which
vacated, reversed, and remanded.308
Justice Breyer briefly concurred, calling the Court’s ruling a “reasonable
interpretation,” but also invited the FDA, when they gained more experience with the
BPCIA, to modify this interpretation.309
Thus, the Court interpreted the first stage of the BPCIA process so as to not
require the biosimilar biologic applicant to engage in the “patent dance,” but suffer the
consequence of a patent infringement lawsuit, as per the statute, if they didn’t. In the
second stage, the commercial marketing notice may be given immediately upon
application, under the BPCIA, and the applicant does not need to wait 180 days after
licensure if the notice is given before then.310 Both of these rulings are reasonable and
consistent with the statutory language, in this author’s opinion.
VIII. CONCLUSION
The U.S. Supreme Court in the 2016-17 term decided six patent cases,311 a tie for
a record-setting term of the Court, and each case reversed or vacated, or both, the
Court of Appeals for the Federal Circuit, four unanimously, and two with one dissenter.
This sends a strong message to the Federal Circuit, to review and adhere to Supreme
Court precedent, which should be the starting point in the analysis, and not the
appeals court’s own precedent. Each case is important and adds to patent
jurisprudence, and has long-reaching implications.
To summarize, in Samsung Electronics Co., Ltd. v. Apple Inc.312 the Supreme
Court unanimously held that the proper “article of manufacturer” for ascertaining
design patent infringement damages may be a component of an end product, whether
sold separately or not, and not the entire end product, reversing the Court of Appeals
for the Federal Circuit. This is the legally appropriate decision, in this author’s
opinion, as a “manufacture” for patent purposes may include a component of a final
product.313 This outcome makes practical sense as well, as the article of manufacture
may be only a very small portion of the end product, leaving an unfair result if only
the minor component is infringed, and holding otherwise could widen the door for
patent assertion entities which could claim that a design patent they own is infringed
by a very small component of an end product with very large sales. Since the Court
didn’t give a test to ascertain the relevant article of manufacture because the issue
wasn’t properly before them, this protracted design patent litigation could end up at
the U.S. Supreme Court again.
In Life Technologies v. Promega, the Court held seven to zero that supplying “a
substantial portion of the components” of a patented invention from the United States
Id. at *33.
Id. at *33.
310 Sandoz Inc. v. Amgen Inc., Nos. 15-1039 and 1195, 2017 U.S. LEXIS 3723 (U.S. June 12,
2017).
311 Supra notes 2-7.
312 Samsung Electronics Co., Ltd. v. Apple Inc., No. 15-777, 2016 U.S. LEXIS 7419 (U.S. Dec. 6,
2016).
313 Id. at *12-13.
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requires a quantitative and not a qualitative analysis, and means more than one
component is supplied, reversing the Court of Appeals for the Federal Circuit and
remanding.314 The Court did not mention extraterritoriality, nor did it give a test on
how to identify “components,” nor how close to all the “substantial portion” must be,
since these last two issues were not before the Court.315
In SCA Hygiene Products v. First Quality Baby Products, LLC,316 the
Court
held seven to one, with Justice Breyer dissenting, that the defense of laches does not
apply during the six-year patent statute of limitations, vacating the en banc decision
of the Court of Appeals for the Federal Circuit and remanding. This is consistent with
the Court’s 2014 holding in Petrella v. Metro-Goldwyn-Mayer,317 under which the
copyright defense of laches did not apply during the copyright three-year statute of
limitations.
In TC Heartland v. Kraft Foods Group,318 the Court held eight to zero that a
corporation resides only in its state of incorporation for purposes of the specific patent
venue statute, reversing the Court of Appeals for the Federal Circuit and
remanding.319 The term “patent troll” was not actually used in this case, since Kraft
is obviously not a patent troll, nor was the term used by the Court at all in 2017, as it
was by the late Justice Scalia in the dissent in Commil USA, LLC v. Cisco Systems,
Inc. in 2015.320 But TC Heartland v. Kraft Foods Group will have the effect of limiting
jurisdiction in patent infringement litigation against domestic corporations, and thus
will have the practical result of reigning in the ability of patent trolls to file suit in
favorable jurisdictions. So, this is an extremely important patent ruling this term,
curtailing patent infringement plaintiffs’ ability to select friendly forums.
In Impression Products, Inc. v. Lexmark Int’l. Inc.,321 the Court on May 30, 2017
held eight to zero that the first domestic sale of a patented good exhausts the patent
holder’s rights under patent law, and seven to one that the first international sale does
the same, reversing the Court of Appeals for the Federal Circuit. This is a very
important decision in the global and international supply chain. This case will have
the practical effect of having many companies across many sectors dealing with the
problem of arbitrage and international re-importation. After Lexmark, valid contracts
may continue to be used with users restricting what they may do with the products,
but patent exhaustion will be a complete defense after the first domestic or
international sale.
In Sandoz, Inc. v. Amgen, Inc., the Court unanimously held on June 12, 2017 that
an injunction is not the statutory remedy under the BPCIA for a biosimilar biologic
314 Life Technologies Corp. v. Promega Corp., No. 14-1538, 2017 U.S. LEXIS 1428 at *17-18 (U.S.
Feb. 22, 2017).
315 Life Technologies Corp. v. Promega Corp., No. 14-1538, 2017 U.S. LEXIS 1428 at *16 note 2,
(U.S. Feb. 22, 2017).
316 SCA Hygiene Products Aktiebolag v. First Quality Baby Products, LLC. No. 15-927, 2017 U.S.
LEXIS 2023 (U.S. Mar. 21, 2017).
317 134 S. Ct. 1962 (2014).
318 TC Heartland v. Kraft Foods Group Brands LLC, No. 16-341, 2017 U.S. LEXIS 3213 (U.S. May
22, 2017).
319 Id.
320 191 L. Ed. 2d 283 (2015).
321 No. 15-1189, 2017 U.S. LEXIS 3397 (U.S. May 30, 2017).
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applicant who does not comply with the preliminary stage of fully notifying the
reference product sponsor within 20 days of the application, and further, the second
notice of commercial marketing may be given by the applicant to the reference product
sponsor before licensure.322 In Sandoz, the Court of Appeals for the Federal Circuit
became both reversed and vacated, and the case remanded. In this author’s opinion,
this result is fully consistent with the statutory language of the BPCIA.
The year 2017, like prior years, was not a good year for patent assertion entities
at the United States Supreme Court. The Court in 2017 struck a blow against patent
trolls in Kraft by limiting the jurisdiction in which patent infringement cases may be
brought against domestic corporations.323 The Court applied copyright precedent in
the patent setting in two cases, SCA Hygiene324 and Impression Products.325 In Apple,
patent infringement damages are not necessarily the total damages of the final
product, when only one component infringes.326 The Court applied common sense
interpretation to the BPCIA in Sandoz.327 The Court properly did not reach beyond
issues before it, leaving some issues to potentially reach the Court again, but in every
case, reversed or vacated the Court of Appeals for the Federal Circuit, six times
unanimously and twice with only one dissenter, which perhaps is the big story from
the Court this term.

Nos. 15-1039 and 15-1195, 2017 U.S. LEXIS 3776 (U.S. June 12, 2017).
Supra notes 156-190 and accompanying text.
324 Supra notes 121-155 and accompanying text.
325 Supra notes 191-250 and accompanying text.
326 Supra notes 29-75 and accompanying text.
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